This is a contrast between Sage Therapeutics Inc. (NASDAQ:SAGE) and Galapagos NV (NASDAQ:GLPG) based on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sage Therapeutics Inc.||168||5110.23||N/A||-9.74||0.00|
Table 1 highlights Sage Therapeutics Inc. and Galapagos NV’s gross revenue, earnings per share (EPS) and valuation.
Table 2 shows us Sage Therapeutics Inc. and Galapagos NV’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Sage Therapeutics Inc.||0.00%||-43.5%||-40.6%|
The table delivered features the ratings and recommendations for Sage Therapeutics Inc. and Galapagos NV.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Sage Therapeutics Inc.||0||0||6||3.00|
Sage Therapeutics Inc. has a consensus price target of $213.33, and a 33.86% upside potential. On the other hand, Galapagos NV’s potential upside is 6.29% and its average price target is $172.6. Based on the analysts view we can conclude, Sage Therapeutics Inc. is looking more favorable than Galapagos NV.
Insider & Institutional Ownership
Sage Therapeutics Inc. and Galapagos NV has shares owned by institutional investors as follows: 98.75% and 16.78%. Insiders owned roughly 1.2% of Sage Therapeutics Inc.’s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Sage Therapeutics Inc.||-8.19%||-12.82%||-3.85%||20.87%||6.31%||67.39%|
For the past year Sage Therapeutics Inc.’s stock price has smaller growth than Galapagos NV.
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Galapagos NV, a clinical-stage biotechnology company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. The companyÂ’s clinical stage programs include filgotinib, which is in Phase III clinical trial for the treatment of rheumatoid arthritis, CrohnÂ’s disease, and ulcerative colitis; GLPG1690, which is in Phase IIa clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972, which is in Phase 1 clinical trial for the treatment of osteoarthritis; and MOR106 that is in atopic dermatitis (AtD) patients in Phase Ib trial. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. It also has a research and development agreement with Pharnext SA to develop a pipeline of synergistic drug combinations for various indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.